Trilaciclib: all 40 studies that test it

Page 1 of 1. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.

• Trilaciclib Combined With Immunochemotherapy for R/M HNSCCNot yet recruitingNCT07679997Phase 2
• Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid TumorsRecruitingNCT07490236Phase 1
• Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung CancerRecruitingNCT07473128Phase 3
• Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Not yet recruitingNCT07255612Phase 2
• Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06992739Phase 2
• Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBCRecruitingNCT06955156Phase 2
• Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCCRecruitingNCT06752798Phase 2
• Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of OsteosarcomaRecruitingNCT06714383Phase 2
• Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06714266Phase 2
• Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and CarboplatinRecruitingNCT06698965Phase 2
• A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma PatientsRecruitingNCT06569485Phase 2
• Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal CancerRecruitingNCT06569459Phase 2
• Trilaciclib Prevents Myelosuppression With ChemoradiotherapyRecruitingNCT06490081Phase 2
• the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With TrilaciclibEnrolling by invitationNCT06370416Phase 2
• A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.Not yet recruitingNCT06364904Phase 3
• A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal MetastasisRecruitingNCT06332287Phase 2
• A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLCRecruitingNCT06328049Phase 2
• Myeloprotection With Trilaciclib in Pan-cancer PopulationNot yet recruitingNCT06297811Phase 2
• Trilaciclib Combined With Chemotherapy for Perioperative Treatment of OsteosarcomaNot yet recruitingNCT06217003Phase 2
• A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic CancerRecruitingNCT06151262Phase 2
• Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLCNot yet recruitingNCT05910034Phase 2
• Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung CancerNot yet recruitingNCT05900921Phase 2
• The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBCNot yet recruitingNCT05862610Phase 2
• Study of Trilaciclib and LurbinectidinRecruitingNCT05578326Phase 2
• Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerTerminatedNCT05113966Phase 2Results posted
• Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerCompletedNCT05112536Phase 2Results posted
• Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer PatientsCompletedNCT04902885Phase 3Results posted
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then AvelumabTerminatedNCT04887831Phase 2Results posted
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)TerminatedNCT04863248Phase 2Results posted
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):TerminatedNCT04607668Phase 3Results posted
• Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLCCompletedNCT03041311Phase 2Results posted
• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)TerminatedNCT02978716Phase 2Results posted
• Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan ChemotherapyCompletedNCT02514447Phase 1/2Results posted
• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)CompletedNCT02499770Phase 1/2Results posted
• A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung CancerActive, not recruitingNCT07881705Phase 3
• Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06027268Phase 2
• Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving TopotecanActive, not recruitingNCT05874401Phase 4
• Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world StudyCompletedNCT05071703Phase 4
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT04799249Phase 3
• Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerActive, not recruitingNCT03425838Phase 3

← Trilaciclib overview